In human CD34+ cell immune-reconstituted NOD scid gamma mice (NSG) mice, Mosunetuzumab significantly reduced B cells and increased CD8+ T cells on days 7, 14, and 21 post-treatment.[21] In a human CD34+ cell immune-reconstituted NSG mice subcutaneously implanted with WSU diffuse large B cell lymphoma (DLCL2) tumor cells, Glofitamab induced rapid and complete clearance of B cells in peripheral blood within 24 h after the first administration. This evidence concerns the gene CD34 and diffuse large B-cell lymphoma.